ARTICLE | Emerging Company Profile
Teasing out Th1
EpiThany's strategy for creating more potent therapeutic cancer vaccines
August 18, 2017 4:53 PM UTC
EpiThany Inc. aims to increase the potency of therapeutic cancer vaccines by designing antigens that selectively activate immune-stimulating Th1 cells, without incurring the immunosuppressive effects caused by Th2 cell activation.
Like most cancer vaccines in development, EpiThany's deliver self-antigens -- pieces of proteins normally found in the body but produced at much higher levels in tumor cells than in healthy cells...
BCIQ Company Profiles